Drug Profile
LOR 2040
Alternative Names: GTI-2040; LOR-2040Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Lorus Therapeutics
- Developer Aptose Biosciences
- Class Antineoplastics; Oligodeoxyribonucleotides
- Mechanism of Action DNA synthesis inhibitors; Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Bladder cancer; Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Prostate cancer; Renal cancer
Most Recent Events
- 04 Sep 2015 No recent reports on development identified - Phase-I for Chronic myeloid leukaemia in USA (IV)
- 04 Sep 2015 No recent reports on development identified - Phase-I for Myelodysplastic syndromes in USA (IV)
- 04 Sep 2015 No recent reports on development identified - Phase-II for Acute myeloid leukaemia (Combination therapy) in USA (IV)